Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Julia Scarisbrick et al.|The Lancet|2017Cited by 580
An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myelomaRavi Vij, Susie Jun, Noemi Horvath et al.|American Journal of Hematology|2009Cited by 97